Barclays Adjusts Elevance Health (ELV) PT to $393 While Maintaining Overweight Rating

Elevance Health Inc. (NYSE:ELV) is one of the most undervalued large cap stocks to invest in now.. On January 30, Barclays lowered the firm’s price target on Elevance Health to $393 from $404 and kept an Overweight rating on the shares.

On January 29, Guggenheim analyst Jason Cassorla also lowered the firm’s price target on Elevance Health to $396 from $414 and maintained a Buy rating on recalibrated 2026 estimates following the company’s Q4 2025 report.

However, on the same day, Deutsche Bank raised the firm’s price target on Elevance Health Inc. (NYSE:ELV) to $332 from $320 while maintaining a Hold rating on the shares. This decision was made as the firm suggested that the company’s 2026 outlook may represent a floor.

15 States with the Best Healthcare in the US

Furthermore, UBS also lowered the firm’s price target on Elevance Health to $400 from $425 with a Buy rating.

Elevance Health Inc. (NYSE:ELV), together with its subsidiaries, operates as a health benefits company in the US. It has four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.